Tuberculosis: Resurgence and Challenges in Modern Ethiopia

Tuberculosis has haunted humanity for centuries, yet its story is one of both triumph and tragedy. Once known as the “White Plague,” TB decimated populations across Europe and North America during the 19th century. After decades of decline, this ancient disease has made a troubling comeback in many parts of the world, including Ethiopia. Understanding this resurgence requires looking at both the past and present, examining why a disease once thought to be nearly conquered remains a critical public health challenge today.

A disease that shaped history 🔗

During the 1800s, tuberculosis was the leading cause of death in industrialized nations. One in four deaths in Europe were attributed to TB, earning it the grim nickname “Captain Among these Men of Death.” The disease thrived in crowded urban centers during the Industrial Revolution, where poor living conditions and malnutrition created ideal conditions for transmission. By the late 19th century, it’s estimated that 70 to 90 percent of urban populations in Europe and North America were infected with the tuberculosis bacteria.

The tide began to turn in the late 1800s and early 1900s, though not because of medicine. Mortality rates declined as sanitation improved and living conditions became better. Robert Koch’s 1882 discovery that TB was caused by bacteria-not heredity-helped establish it as a contagious disease requiring public health measures. The development of effective antibiotics in the 1940s and 1950s accelerated this decline dramatically, leading many to believe TB would soon be eliminated entirely.

Why tuberculosis came roaring back 🔗

The optimism of the mid-20th century proved premature. Starting in the 1980s and accelerating through the 1990s, TB cases began rising again in many regions. This resurgence wasn’t random-it was driven by several interconnected factors that created perfect conditions for the disease to spread once more.

The HIV/AIDS pandemic 🔗

The most significant driver of TB’s return has been the HIV/AIDS epidemic. People living with HIV face up to 20 times higher risk of developing TB compared to those without HIV infection. HIV weakens the immune system, making it far easier for dormant TB infections to become active disease. This deadly partnership has been particularly devastating in sub-Saharan Africa, where both diseases are highly prevalent.

Drug resistance emerges 🔗

Another major factor has been the development of drug-resistant strains of TB. When patients don’t complete their full course of treatment-often due to poverty, lack of access to healthcare, or inadequate health systems-the bacteria can develop resistance to standard medications. Multidrug-resistant TB (MDR-TB) is resistant to the two most powerful first-line drugs, while extensively drug-resistant TB (XDR-TB) is even harder to treat. These resistant strains require longer treatment periods, more expensive medications, and result in poorer outcomes for patients.

Poverty and weakened health systems 🔗

The dismantling of TB control programs in many countries during the 1980s and 1990s, combined with persistent poverty and overcrowding, created additional openings for the disease. When public health infrastructure weakens, TB finds opportunities to spread. Inadequate nutrition, poor housing, and limited healthcare access all contribute to higher TB rates, particularly among vulnerable populations.

Tuberculosis in Ethiopia today 🔗

Ethiopia faces a substantial TB burden, classified as a high-burden country by the World Health Organization. The intersection of HIV and TB creates particularly complex challenges. Research shows that about 15 percent of adults living with HIV in Ethiopia also have pulmonary tuberculosis, significantly higher than the general population.

The Ethiopian Ministry of Health, supported by international partners like the CDC through PEPFAR, has been working to address this dual epidemic. In 2024, over 5,600 people living with HIV were diagnosed and treated for TB, while more than 31,000 received preventive treatment to stop latent infections from becoming active disease. These efforts have achieved an 86 percent completion rate, showing that well-designed programs can make real progress.

Despite these gains, challenges remain. Ethiopia’s TB incidence rate stands at 146 cases per 100,000 population, with significant regional variations. The Afar Region, a predominantly pastoral area, shows particularly high co-infection rates. Access to quality diagnostics, treatment adherence, and reaching remote populations continue to test the healthcare system’s capacity.

Key factors affecting TB control in Ethiopia 🔗

Several specific challenges affect Ethiopia’s TB response. Low CD4 counts among people living with HIV significantly increase TB risk, as do advanced HIV disease stages. Poverty, malnutrition, and limited health infrastructure in rural areas make both prevention and treatment more difficult. Additionally, population mobility-particularly among pastoral communities-complicates efforts to ensure consistent treatment and follow-up care.

Learning from global approaches 🔗

The international community has developed several strategies to combat TB that offer valuable lessons for Ethiopia and other high-burden countries. Understanding these approaches can help strengthen national responses and accelerate progress toward TB control.

The DOTS strategy and beyond 🔗

The WHO’s DOTS (Directly Observed Treatment, Short-Course) strategy, introduced in 1995, revolutionized TB control by establishing standardized treatment protocols. DOTS includes five key components: political commitment, quality microscopy for diagnosis, uninterrupted drug supply, direct observation of treatment, and systematic monitoring of outcomes. While DOTS has been credited with saving millions of lives, it has limitations, particularly in detecting new cases and addressing drug resistance.

The End TB Strategy 🔗

Recognizing these limitations, WHO launched the End TB Strategy in 2014 with more ambitious goals: reducing TB incidence by 80 percent and deaths by 90 percent by 2030. This comprehensive approach goes beyond medical treatment to address social determinants of health. It emphasizes patient-centered care, bold policies that engage multiple sectors beyond health ministries, and intensified research and innovation. The strategy acknowledges that ending TB requires addressing poverty, improving living conditions, and ensuring universal health coverage.

Integrated TB/HIV services 🔗

For countries like Ethiopia with high HIV prevalence, integrating TB and HIV services has proven essential. This means screening all people living with HIV for TB at every clinic visit, providing preventive treatment to those at risk, and ensuring coordinated care for co-infected individuals. Enhanced case-finding strategies, household investigations, and expanded use of TB preventive treatment can significantly reduce disease burden among vulnerable populations.

New diagnostics and shorter treatments 🔗

Advances in rapid molecular testing allow for quicker, more accurate TB diagnosis, including detection of drug resistance. Shorter treatment regimens for drug-resistant TB-some as brief as six months compared to the traditional 18-24 months-improve patient adherence and outcomes. Ethiopia’s adoption of these innovations, supported by international partners, represents an important step forward, though ensuring equitable access across all regions remains challenging.

Building on progress 🔗

Ethiopia’s experience illustrates both the possibilities and challenges of TB control in resource-limited settings. The country has made significant strides in expanding DOTS coverage, integrating TB and HIV services, and improving treatment outcomes. Electronic medical records now cover 95 percent of HIV treatment facilities, enabling better tracking and data-driven decision-making. Virtual support during the COVID-19 pandemic showed that innovative approaches can maintain momentum even during crises.

Yet much work remains. Expanding TB preventive treatment coverage, strengthening diagnostic capacity in remote areas, addressing social determinants like poverty and malnutrition, and ensuring consistent drug supplies all require sustained commitment and resources. The involvement of communities, civil society, and multiple government sectors-not just health ministries-will be critical for long-term success.

The story of tuberculosis-from 19th-century plague to modern-day epidemic-reminds us that infectious diseases don’t simply disappear because we wish them away. They require sustained attention, adequate resources, and comprehensive strategies that address both medical and social factors. Ethiopia’s ongoing efforts, supported by global partnerships and evidence-based strategies, offer hope that this ancient disease can finally be brought under control.

What do you think? How can countries balance immediate treatment needs with long-term prevention strategies when resources are limited? What role should international partnerships play in supporting national TB control programs while ensuring local ownership and sustainability?

References

1. https://en.wikipedia.org/wiki/History_of_tuberculosis
2. https://curiosity.lib.harvard.edu/contagion/feature/tuberculosis-in-europe-and-north-america-1800-1922
3. https://www.cdc.gov/global-hiv-tb/php/success-stories/scaling-tpt-ethiopia.html
4. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-10419-8
5. https://www.cdc.gov/global-hiv-tb/php/where-we-work/ethiopia.html
6. https://www.ncbi.nlm.nih.gov/books/NBK310770/
7. https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy